Last reviewed · How we verify
Triple-targeted CAR-T Therapy
At a glance
| Generic name | Triple-targeted CAR-T Therapy |
|---|---|
| Sponsor | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers (PHASE1)
- Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells (PHASE1)
- Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma (PHASE1)
- T-Cell Therapy for Advanced Breast Cancer (PHASE1)
- A Study to Investigate LYL797 in Adults With Solid Tumors (PHASE1)
- KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer (PHASE1)
- A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers (PHASE1)
- cMet CAR RNA T Cells Targeting Breast Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: